MEDSIR, a leading international company in oncology research, has announced the results of the PHERGuide study during the 2025 San Antonio Breast Cancer Symposium (SABCS). This research, presented as ...
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA ...
Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...
BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...
Menarini Silicon Biosystems, a pioneer of cell-based liquid biopsy technology, announced today the publication in Clinical ...
Early ctDNA clearance, combined with complete response on PET-CT, correlates with prolonged progression-free survival. ctDNA testing is minimally invasive and can be conducted repeatedly, offering a ...
LA JOLLA, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the development and application ...
News-Medical.Net on MSN
Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA ...
A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback